345 related articles for article (PubMed ID: 24841238)
21. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
22. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
Blood; 2009 Jun; 113(24):6161-71. PubMed ID: 19372261
[TBL] [Abstract][Full Text] [Related]
23. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
24. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
Rao V; Gordon C
Immunotherapy; 2014; 6(11):1165-75. PubMed ID: 25496332
[TBL] [Abstract][Full Text] [Related]
26. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Robak E; Robak T
Curr Drug Targets; 2009 Jan; 10(1):26-37. PubMed ID: 19149533
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
29. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
30. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
31. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
33. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
35. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
36. Targeting CD22 as a strategy for treating systemic autoimmune diseases.
Dörner T; Goldenberg DM
Ther Clin Risk Manag; 2007 Oct; 3(5):953-9. PubMed ID: 18473018
[TBL] [Abstract][Full Text] [Related]
37. CD22 and autoimmune disease.
Dörner T; Shock A; Smith KG
Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
[TBL] [Abstract][Full Text] [Related]
38. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
39. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
40. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T; Tanaka Y; Kishimoto M; Saito K; Yoshizawa S; Takasaki Y; Miyamura T; Niiro H; Morimoto S; Yamamoto J; Lledo-Garcia R; Shao J; Tatematsu S; Togo O; Koike T
Mod Rheumatol; 2016; 26(1):87-93. PubMed ID: 26382733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
